ALNYLAM PHARMACEUTICALS, INC. Increase (Decrease) in Contract with Customer, Liability
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Increase (Decrease) in Contract with Customer, Liability of -$831.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $2.31M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$12.54M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-06-30 was -$13.08M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-03-31 was -$27.32M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$50.63M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was -$235.45M, a 527.91% decline from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was $55.02M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was -$65.91M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 9 month as first filed | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$831.00K 10-Q · filed 2026-07-30 | ||||
| 2025-12-31 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$10.23M derived: sum of 2 quarters · filed 2026-02-12 | -$23.31M derived: sum of 3 quarters · filed 2026-07-30 | -$50.63M 10-K · filed 2026-02-12 | |
| 2025-09-30 | -$12.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$25.62M derived: sum of 2 quarters · filed 2026-07-30 | -$52.94M 10-Q · filed 2025-10-30 | -$65.75M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | -$13.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$40.40M 10-Q · filed 2026-07-30 | -$53.21M derived: sum of 3 quarters · filed 2026-07-30 | -$56.34M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | -$27.32M 10-Q · filed 2025-05-01 | -$40.13M derived: sum of 2 quarters · filed 2026-02-12 | -$43.26M derived: sum of 3 quarters · filed 2026-02-12 | -$234.20M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-12-31 | -$12.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$15.94M derived: sum of 2 quarters · filed 2026-02-12 | -$206.88M derived: sum of 3 quarters · filed 2026-02-12 | -$235.45M 10-K · filed 2026-02-12 | |
| 2024-09-30 | -$3.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$194.07M derived: sum of 2 quarters · filed 2025-10-30 | -$222.64M 10-Q · filed 2025-10-30 | -$218.88M 10-Q · filed 2024-10-31 | -$204.95M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$190.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$219.51M 10-Q · filed 2025-07-31 | -$201.82M derived: sum of 3 quarters · filed 2026-02-12 | -$177.35M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-03-31 | -$28.56M 10-Q · filed 2025-05-01 | -$10.87M derived: sum of 2 quarters · filed 2026-02-12 | $13.59M derived: sum of 3 quarters · filed 2026-02-12 | $35.31M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2023-12-31 | $17.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $42.16M derived: sum of 2 quarters · filed 2026-02-12 | $63.87M derived: sum of 3 quarters · filed 2026-02-12 | $55.02M 10-K · filed 2026-02-12 | |
| 2023-09-30 | $24.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $46.18M derived: sum of 2 quarters · filed 2024-10-31 | $37.33M 10-Q · filed 2024-10-31 | -$3.95M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-06-30 | $21.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $12.87M 10-Q · filed 2024-08-01 | -$28.41M derived: sum of 3 quarters · filed 2025-02-13 | -$40.88M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-03-31 | -$8.85M 10-Q · filed 2024-05-02 | -$50.13M derived: sum of 2 quarters · filed 2025-02-13 | -$62.59M derived: sum of 3 quarters · filed 2025-02-13 | -$62.44M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2022-12-31 | -$41.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$53.74M derived: sum of 2 quarters · filed 2025-02-13 | -$53.59M derived: sum of 3 quarters · filed 2025-02-13 | -$65.91M 10-K · filed 2025-02-13 | |
| 2022-09-30 | -$12.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$12.31M derived: sum of 2 quarters · filed 2023-11-02 | -$24.63M 10-Q · filed 2023-11-02 | -$14.94M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-06-30 | $158.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$12.17M 10-Q · filed 2023-08-03 | -$2.48M derived: sum of 3 quarters · filed 2024-02-15 | -$10.83M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-03-31 | -$12.32M 10-Q · filed 2023-05-04 | -$2.63M derived: sum of 2 quarters · filed 2024-02-15 | -$10.99M derived: sum of 3 quarters · filed 2024-02-15 | -$34.92M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2021-12-31 | $9.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $1.34M derived: sum of 2 quarters · filed 2024-02-15 | -$22.60M derived: sum of 3 quarters · filed 2024-02-15 | -$50.40M 10-K · filed 2024-02-15 | |
| 2021-09-30 | -$8.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | -$32.29M derived: sum of 2 quarters · filed 2022-10-27 | -$60.09M 10-Q · filed 2022-10-27 | -$88.14M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | -$23.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-28 | -$51.74M 10-Q · filed 2022-07-28 | -$79.78M derived: sum of 3 quarters · filed 2023-02-23 | -$88.62M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | -$27.80M 10-Q · filed 2022-04-28 | -$55.84M derived: sum of 2 quarters · filed 2023-02-23 | -$64.68M derived: sum of 3 quarters · filed 2023-02-23 | -$67.74M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | -$28.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$36.88M derived: sum of 2 quarters · filed 2023-02-23 | -$39.94M derived: sum of 3 quarters · filed 2023-02-23 | -$43.97M 10-K · filed 2023-02-23 | |
| 2020-09-30 | -$8.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | -$11.89M derived: sum of 2 quarters · filed 2021-10-28 | -$15.92M 10-Q · filed 2021-10-28 | -$23.26M derived: sum of 4 quarters · filed 2022-02-10 | |
| 2020-06-30 | -$3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$7.09M 10-Q · filed 2021-08-03 | -$14.42M derived: sum of 3 quarters · filed 2022-02-10 | -$14.01M derived: sum of 4 quarters · filed 2022-02-10 | |
| 2020-03-31 | -$4.03M 10-Q · filed 2021-04-29 | -$11.36M derived: sum of 2 quarters · filed 2022-02-10 | -$10.95M derived: sum of 3 quarters · filed 2022-02-10 | $389.06M derived: sum of 4 quarters · filed 2022-02-10 | |
| 2019-12-31 | -$7.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | -$6.92M derived: sum of 2 quarters · filed 2022-02-10 | $393.08M derived: sum of 3 quarters · filed 2022-02-10 | $392.25M 10-K · filed 2022-02-10 | |
| 2019-09-30 | $411.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $400.42M derived: sum of 2 quarters · filed 2020-11-05 | $399.58M 10-Q · filed 2020-11-05 | $398.47M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-06-30 | $400.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $399.17M 10-Q · filed 2020-08-06 | $398.06M derived: sum of 3 quarters · filed 2021-02-11 | $389.44M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-03-31 | -$834.00K 10-Q · filed 2020-05-06 | -$1.95M derived: sum of 2 quarters · filed 2021-02-11 | -$10.56M derived: sum of 3 quarters · filed 2021-02-11 | -$40.41M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2018-12-31 | -$1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$9.73M derived: sum of 2 quarters · filed 2021-02-11 | -$39.58M derived: sum of 3 quarters · filed 2021-02-11 | -$12.62M 10-K · filed 2021-02-11 | |
| 2018-09-30 | -$8.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$38.46M derived: sum of 2 quarters · filed 2019-10-31 | -$11.50M 10-Q · filed 2019-10-31 | -$3.61M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-06-30 | -$29.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$2.89M 10-Q · filed 2019-08-06 | $5.00M derived: sum of 3 quarters · filed 2020-02-13 | ||
| 2018-03-31 | $26.96M 10-Q · filed 2019-05-02 | $34.85M derived: sum of 2 quarters · filed 2020-02-13 | |||
| 2017-12-31 | $7.89M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $1.85M 10-K · filed 2020-02-13 | |||
| 2017-09-30 | -$6.04M 10-Q · filed 2018-11-07 | ||||
| 2016-12-31 | $14.62M 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |